NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

TransformingPersonalized Medicine

Image for About NeoStem

About NeoStem

NeoStem is a biopharmaceutical company developing novel cell based personalized medicine therapies.

Learn More

 

TargetingCancer

Image for Metastatic melanoma

Metastatic melanoma

NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.

Learn More 

Enhancingthe body’s healing response

Image for Acute myocardial infarction – STEMI

Acute myocardial infarction – STEMI

NeoStem is developing a cell therapeutic applicable for multiple cardiovascular indications with an ongoing Phase 2 study for acute myocardial infarction.

Learn More

Rebalancingthe immune system

Image for Type 1 diabetes

Type 1 diabetes

NeoStem is developing an immunomodulation therapeutic platform targeting type 1 diabetes and other autoimmune disorders.

Learn More

Innovatingdevelopment and manufacturing of cell-based therapies

Image for Client Services

Client Services

NeoStem’s subsidiary, PCT, provides development manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.

Learn More

News + Events

News + Events

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results March 16, 2015 - Learn More
 
NeoStem to Present at Two Upcoming Investor Conferences in March March 12, 2015 - Learn More 
 
NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update March 2, 2015 - Learn More

NeoStem Blog

CEO Letter to NeoStem Shareholders

Dear NeoStem Shareholders, As you might imagine, the first two months of my tenure as the Chief Executive O.... Read More

Strengthening NeoStem’s Executive Management with Two Significant Hires

After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. Dav.... Read More